New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Ontario residents eligible for ODB and ...
New registry study data shows that long-term use of Dexcom G7 supports weight management and lowers A1C for people with Type 2 diabetes who aren’t on insulin therapy 1, reinforcing the need to broaden ...
The only peer-reviewed journal covering all aspects of diagnosing and managing diabetes with cutting-edge devices, drugs, drug delivery systems, and software. In a new study in the peer-reviewed ...
Medicare Part B typically covers continuous glucose monitors (CGMs) like the Dexcom G7, as they are Food and Drug Administration (FDA)-approved durable medical equipment items. To get a Dexcom G7 CGM ...
Dexcom reaffirmed its 2025 revenue guidance of $4.6 billion, representing 14% growth. The company also maintained its operating margin and adjusted EBITDA margin guidance at approximately 21% and 30%, ...
MARKHAM, Ontario--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by Health Canada, in-warranty t:slim X2™ ...
BARCELONA, Spain--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results